000			nab a22 7a 4500
999			_c17771 _d17771
003			PC17771
005			20231204111140.0
008			231204b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9389 _aMartínez López, Joaquín _eHematología y Hemoterapia
245	0	0	_aElotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. _h[artículo]
260			_bBritish journal of haematology, _c2016
300			_a175(3):448-56.
500			_aFormato Vancouver: Mateos MV, Granell M, Oriol A, Martínez López J, Blade J, Hernandez MT et al. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2016 Nov;175(3):448-56.
501			_aPMID: 27434748
504			_aContiene 37 referencias
520			_aElotuzumab is an immunostimulatory, humanized immunoglobulin G1 monoclonal antibody that selectively targets and kills signalling lymphocytic activation molecule family member 7-expressing myeloma cells. We evaluated the safety and tolerability of elotuzumab 10 mg/kg combined with thalidomide 50-200 mg and dexamethasone 40 mg (with/without cyclophosphamide 50 mg) in patients with relapsed/refractory multiple myeloma (RRMM). The primary endpoint was the proportion of grade ≥3 non-haematological adverse events (AEs); other endpoints included the number of dose reductions/discontinuations and efficacy. Forty patients were treated, who had a median of three previous therapies, including bortezomib (98%) and lenalidomide (73%). Grade ≥3 non-haematological AEs were reported in 63% of patients, most commonly asthenia (35%) and peripheral oedema (25%). Six (15%) patients had an infusion reaction. Twenty-six (65%) patients had ≥1 dose reduction/discontinuation due to an AE, none related to elotuzumab. Overall response rate was 38%; median progression-free survival was 3·9 months. Median overall survival was 16·3 months and the 1-year survival rate was 63%. Minimal incremental toxicity was observed with addition of elotuzumab to thalidomide/dexamethasone with or without cyclophosphamide, and efficacy data suggest clinical benefit in a highly pre-treated population. Elotuzumab combined with thalidomide may provide an additional treatment option for patients with RRMM.
710			_9297 _aServicio de Hematología y Hemoterapia
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17771.pdf _ySolicitar documento
942			_2ddc _cART _n0